a year ago
LabGenius Raises €40.1 Million to Develop ML-Driven Antibody Discovery Platform
London-based LabGenius, a drug discovery company using machine learning for antibody discovery, has closed a €40.1 million Series B financing round
The company will use the funds to progress its ML-driven discovery platform and pipeline of multispecific antibodies towards the clinic.
ProblemTechnology
"Developing new therapeutic antibodies is a complex and time-consuming process. Traditional methods often struggle to optimize antibodies for multiple properties simultaneously, leading to inefficient development and potential performance losses. Additionally, many therapeutic antibodies face challenges with on-target, off-tumor toxicity, where they target healthy cells alongside diseased cells, leading to harmful side effects."
Solution
"LabGenius has developed a unique ML-driven platform called EVA™ that uses a smart robotic system to design, conduct, and learn from its own experiments. This platform enables the rapid identification of high-performing antibodies with non-intuitive designs. EVA™ utilizes Multi-Objective Bayesian Optimization (MOBO) to efficiently co-optimize antibodies across multiple key properties, including potency, efficacy, developability, and tumor selectivity. This approach eliminates human bias and delivers superior results compared to conventional methods."
